Key Quantitative Figures & Performance Highlights

Overall Financial Performance (Q1 FY27):

  • Total Revenue from Operations: INR 8,277 crores (32% YoY growth)
  • EBITDA (excluding forex and other income): INR 2,464 crores (50% YoY growth)
  • EBITDA Margin: 30% (340 basis points improvement YoY)
  • Gross Margin: 74.6% (330 basis points improvement YoY from 71.3% in Q1FY26)
  • Net Cash: INR 2,831 crores as of June 30, 2026 (decreased from INR 4,636 crores as of March 31, 2026, due to VISUfarma acquisition closure)
  • ROCE: 29.5% (vs. 28.4% at end of FY26)
  • R&D Spend: INR 608 crores (7.4% of sales)
  • Effective Tax Rate (ETR): 29.8% for the quarter (full-year expectation 27%-28%)
  • Operating Working Capital: INR 8,260 crores (90 days) as of June 30, 2026 vs. INR 7,132 crores (87 days) as of March 31, 2026

Geographical Business Performance:

  • U.S. Sales: USD 366 million (43% YoY growth in constant currency). FY27 guidance: USD 1.1 billion to USD 1.2 billion.
  • India Region Sales: INR 2,380 crores (13.9% YoY growth). Core prescription business grew 15.1% YoY vs. IPM growth of 13.5%.
  • Other Developed Markets (Europe, Canada, Australia) Sales: INR 1,149 crores (48% YoY growth), accounting for 14% of total sales.
  • Emerging Markets Sales: INR 990 crores (52% YoY growth), led by Brazil (117% YoY growth in local currency), South Africa, and Philippines.
  • Global India Business (GIB): 40% YoY growth.
  • Organic Growth (ex-U.S.): 20%+ YoY.

Operational Metrics (India Business):

  • Volume Growth: 6.1%
  • Chronic segment share: 67% of portfolio (up from ~65% in FY26)
  • Target: Increase chronic share to 70% in next 5 years
  • In-licensed products share: ~6% (similar to FY26 levels)
  • Product Launches: ~7 products in Q1FY27; plan to launch ~20 products in FY27 vs. 15 in FY26

Expense Breakdown:

  • Employee Benefit Expenses: INR 1,383 crores (16.8% of sales vs. 17.6% last year)
  • Manufacturing and Other Expenses: INR 2,341 crores (28.5% of sales vs. 28.7% last year)
  • Other Operating Income: INR 60 crores (decreased 43% YoY due to lower export benefits from PLI schemes)
  • Depreciation & Amortization: INR 453 crores (increase due to higher amortization of settlement agreements)

Pipeline & Product Launches

U.S. Pipeline (Next 3 Years):

  • Plan to launch 50+ products
  • Includes 10 exclusive first-to-files (FTFs)
  • 5 biosimilars
  • 2-3 505(b)(2) products
  • Plan to file more than 15 products in FY27, including at least 7 in Respiratory segment

Key Near-Term Launches (FY27):

  • Pegfilgrastim (biosimilar, H2 launch)
  • Dalbavancin injectable (505(b)(2))
  • Fluticasone nasal spray (Rx approval expected in FY27, OTC in FY28)
  • Sugammadex injection
  • Epinephrine injection
  • Raltegravir injection (exclusive FTF)
  • Eribulin injection

Key Launches (FY28):

  • Full-year impact of Pegfilgrastim
  • Diazepam nasal spray
  • Epinephrine nasal spray
  • Apixaban 505(b)(2) (potential approval in September 2026, launch expected summer 2027)
  • Iron sucrose injectable
  • Saxenda®
  • Ivacaftor (exclusive FTF)
  • Midazolam nasal spray
  • Suflave® (exclusive FTF)

Key Launches (FY29 and beyond):

  • More biosimilars (Aflibercept, Pegfilgrastim on-body injector)
  • Dulera® (filed)
  • Spiriva Respimat® (expected to file in FY27)
  • Etanercept (biosimilar, calendar year 2029)
  • Xywav® (FTF, FY33)

Respiratory Portfolio:

  • Current contribution to U.S. business: over 20%
  • Key pipeline products: Dulera® (filed), Spiriva Respimat® (filing in FY27), Breo® Ellipta (pivotal PK successful, ANDA filing expected in FY27)

Biosimilars Opportunity:

  • Expected to ramp up to a couple of hundred million dollars across key markets in the next three years.

India Innovation:

  • Target: One-third of India revenues from novel proprietary products in the next 10 years.
  • Avenues: Internal pipeline, in-licensing deals, and pure innovative NCEs (e.g., Bofanglutide in clinical development).
  • Plan: 60-70 innovative product launches over 10 years.

Guidance & Outlook

FY27 Guidance:

  • Organization: High single-digit revenue growth
  • EBITDA Margins: Around 25%
  • R&D Spend: Around 8% of sales
  • Effective Tax Rate: 27% - 28%

U.S. Business Outlook:

  • Expect moderation in performance from Q2 onwards due to increased competition in Mirabegron and Tolvaptan.
  • Quarterly U.S. sales expected between USD 250 million to USD 280 million over the next couple of quarters.
  • Expect business to revert to growth trajectory from FY28 onwards.

Geographical Growth Expectations:

  • India: Outperform IPM by 1.2x to 1.3x
  • Europe: 10% to 20% growth
  • Other Developed Markets: 10% to 20% growth
  • Emerging Markets: Double-digit growth

Compliance & Manufacturing

Regulatory Updates:

  • Received EIRs with VAI status from U.S. FDA for Ankleshwar and Somerset facilities.
  • For Pithampur Unit II facility: Responses submitted; remediation efforts on track.

Capital Allocation & Strategy

Strategic Focus:

  • Double the share of complex products in U.S. business, led by respiratory and complex injectables, augmented by biosimilars.
  • Grow Europe business with complex generics, biosimilars portfolio, and specialty acquisitions (e.g., VISUfarma).
  • Establish presence in diabetes metabolic space in emerging markets.
  • Continue exploring strategic capital allocation for long-term mission, including specialty front.

ESG:

  • Achieved ~41% reduction in greenhouse gas emissions and 45% water recycling as of FY26.
  • Included in the TIME World's Most Sustainable Companies 2026 List.

Risks & Challenges

  • Increased competitive intensity in U.S. on key products (Mirabegron, Tolvaptan).
  • Uncertain geopolitical environment posing potential headwinds.
  • Some adjacencies (Diagnostics, Digital, OTC, CDMO) are currently loss-making, impacting EBITDA margins by ~1% - 1.5%.